Article
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
The New England journal of medicine - 13 Nov 2014
Long Georgina V, Stroyakovskiy Daniil, Gogas Helen, Levchenko Evgeny, de Braud Filippo, Larkin James, Garbe Claus, Jouary Thomas, Hauschild Axel, Grob Jean Jacques, Chiarion Sileni Vanna, Lebbe Celeste, Mandalà Mario, Millward Michael, Arance Ana, Bondarenko Igor, Haanen John B A G, Hansson Johan, Utikal Jochen, Ferraresi Virginia, Kovalenko Nadezhda, Mohr Peter, Probachai Volodymyr, Schadendorf Dirk, Nathan Paul, Robert Caroline, Ribas Antoni, DeMarini Douglas J, Irani Jhangir G, Casey Michelle, Ouellet Daniele, Martin Anne-Marie, Le Ngocdiep, Patel Kiran, Flaherty Keith
Abstract excerpt
BACKGROUND: Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and reduces toxic effects in patients who have melanoma with BRAF V600E or V600K mutations. METHODS: In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation to receive a combination of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.